Click Here for 5% Off Your First Aladdin Purchase!

abatacept, CAS No.rp173355, Fusion protein of CD80;Fusion protein of CD86

  • Moligand™
Features and benefits
    Item Number
    rp173355
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp173355-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp173355-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90

    Basic Description

    Product Nameabatacept, CAS No.rp173355
    SynonymsBMS-188667;CTLA4-IgG4m;Orencia,RG-1046;RG-2077
    GradeMoligand™
    Action TypeINHIBITOR
    Mechanism of actionFusion protein of CD80;Fusion protein of CD86

    Associated Targets

    CD86 Tclin T-lymphocyte activation antigen CD86 0 Activities

    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    CD80 Tclin T-lymphocyte activation antigen CD80 0 Activities

    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp173355

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate NamesBMS-188667;CTLA4-IgG4m;Orencia,RG-1046;RG-2077
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA.  (1991)  CTLA-4 is a second receptor for the B cell activation antigen B7..  J Exp Med,  174  (3): (561-9).  [PMID:1714933]
    2. Ludvigsson J.  (2016)  Therapies to Preserve β-Cell Function in Type 1 Diabetes..  Drugs,  76  (2): (169-85).  [PMID:26645223]
    3. Davis IC, Randell J, Davis SN.  (2015)  Immunotherapies currently in development for the treatment of type 1 diabetes..  Expert Opin Investig Drugs,  24  (10): (1331-41).  [PMID:26364507]
    4. Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B et al..  (2017)  A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding..  J Immunol,  198  (1): (528-537).  [PMID:27881707]

    Solution Calculators